FDA Approves Lumateperone for Prevention of Relapse in Adults With Schizophrenia

The FDA approved a supplemental new drug application (sNDA) for lumateperone (Caplyta; Johnson & Johnson) for the prevention of relapse in adults with schizophrenia. The label expansion marks a significant milestone for the atypical antipsychotic, positioning lumateperone as an acute treatment option and long-term maintenance therapy aimed at reducing relapse risk and promoting sustained disease stability.¹

Schizophrenia remains one of the most challenging chronic psychiatric disorders to manage, primarily because of its relapsing-remitting nature. Relapse events can have profound consequences for patients, often resulting in psychiatric hospitalization, deterioration in social and occupational functioning, worsening treatment adherence, and increased caregiver burden.^1,2

According to Johnson & Johnson, adults living with schizophrenia experience an average of 9 relapse episodes within a 6-year period, underscoring the importance of maintenance therapies that can preserve symptom control over time. Relapse prevention is therefore a central treatment goal for clinicians seeking to minimize disease progression and improve long-term patient outcomes.^1,2

“Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization,” Christoph U. Correll, MD, clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York, said in a news release. “These phase 3 results…provide [health care professionals] with another tool that can offer long-term stability for people living with schizophrenia.”¹

The FDA’s decision was based on findings from the phase 3 randomized withdrawal trial (NCT04959032)³, a multicenter, double-blind, placebo-controlled study designed to evaluate lumateperone’s efficacy in preventing relapse in adults with schizophrenia. Patients who achieved clinical stability during an open-label treatment phase were randomly assigned to continue receiving 42 mg of lumateperone once per day or switch to placebo during a 26-week double-blind treatment period.^1,3

Results demonstrated that patients who remained on lumateperone experienced an approximate 63% lower risk of relapse compared with those who transitioned to placebo, corresponding to a hazard ratio of about 0.37. Additionally, 84% of patients receiving lumateperone remained relapse-free over a 6-month duration, demonstrating sustained efficacy during the maintenance phase. The treatment also significantly delayed time to all-cause discontinuation, a clinically meaningful endpoint reflecting both therapeutic benefit and tolerability. Statistical significance was strong for the primary end point of time to relapse (P = .0002).^1,4

Equally notable was lumateperone’s safety profile, which remained consistent with previous studies and its established prescribing information. There were no new safety signals that emerged during the trial. The most commonly reported treatment-related adverse event (AE) was headache.^1,4

This latest approval further broadens lumateperone’s clinical utility. Originally approved in 2019 for the treatment of schizophrenia in adults, the drug subsequently gained approvals for depressive episodes associated with bipolar I or II disorder, both as monotherapy and adjunctive therapy with lithium or valproate. More recently, in late 2025, the FDA approved lumateperone as adjunctive therapy with antidepressants for adults with major depressive disorder. The addition of relapse prevention data further reinforces the medication’s versatility across psychiatric indications and reflects growing confidence in its long-term efficacy profile.⁵

For pharmacists, this expanded indication carries important practice implications. Medication adherence remains a critical determinant of schizophrenia outcomes, and relapse frequently follows treatment interruption or discontinuation. Pharmacists can counsel patients on the importance of maintenance therapy, monitor for AEs, identify barriers to adherence, and coordinate with prescribers when tolerability concerns arise. The once-daily dosing and lack of titration requirements may simplify patient education and improve initiation success.

“People living with schizophrenia deserve treatment options that help support stability over time, not just symptom control in the short term,” said Celine Goldberger, MD, PhD, vice president of global medical affairs, neuroscience, and innovative medicine, Johnson & Johnson. “This label update—backed by long-term phase 3 data demonstrating a significant delay in time to relapse—reinforces our commitment to advancing evidence-based therapies to support each patient’s individual needs including a proven therapy that supports stability over time.”¹

REFERENCES

1. Johnson & Johnson. FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia. Press release. April 27, 2026. https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia

2. Ferruggia K. Caplyta from Johnson & Johnson. Pharmacy Times^®. December 24, 2025. Accessed April 28, 2026. https://www.pharmacytimes.com/view/caplyta-from-johnson-johnson

3. ClinicalTrials.gov. Multicenter Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia. ClinicalTrials.gov identifier: NCT04959032. Updated November 7, 2024. Accessed April 28, 2026. https://clinicaltrials.gov/study/NCT04959032

4. Halpern L. Lumateperone demonstrates positive efficacy for schizophrenia relapse prevention. Pharmacy Times. November 11, 2024. Accessed April 28, 2026. https://www.pharmacytimes.com/view/lumateperone-demonstrates-positive-efficacy-for-schizophrenia-relapse-prevention

5. Halpern L. FDA approves lumateperone with antidepressant use for major depressive disorder. Pharmacy Times. November 6, 2025. Accessed April 28, 2026. https://www.pharmacytimes.com/view/fda-approves-lumateperone-with-antidepressant-use-for-major-depressive-disorder